Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : President Barack Obama -- Ignore unavailable to you. Want to Upgrade?

To: RetiredNow who wrote (115058)	6/9/2012 9:36:24 AM
From: Sr K	Read Replies (2) \| Respond to of 149317

It's the big winner in the game Message 28194585 and the reason donc is in first place ARNA $6.42 9.653 $61.97 $2.59 148% Also: Arena Pharmaceuticals, Inc. (NasdaqGS: ARNA - News) recently announced that the European Medicines Agency (:EMA) accepted its marketing authorization application (:MAA) for lorcaserin for review. The application was filed earlier in the month. The news had a positive impact on Arena Pharma’s shares. We note that Arena Pharma and partner Eisai Inc. are looking to get lorcaserin approved for weight management, including weight loss and its maintenance, in obese (Body Mass Index, or BMI, >30) or overweight (BMI >27) patients suffering from at least one weight-related co-morbid condition.